

ERS 2020

ILD program

MONDAY 7 SEPTEMBER

09:30 – 10:30

Oral presentation - New clinical insights into idiopathic pulmonary fibrosis.

Chairs: W. Wuyts (Leuven, Belgium) M. Wijsenbeek (Rotterdam, Netherlands)

Channel 4

11:50 – 12:50

Challenging clinical cases – Interstitial lung diseases

Chairs: M. Kreuter (Heidelberg, Germany) M. Molina-Molina (Barcelona, Spain)

Channel 4

13:30 – 13:55

ERS Roche Live Lunch "What are the treatment challenges for non-IPF ILDs?"

Organized by : F. Hoffmann-La Roche Ltd., Chairs: R. Pandey (Nepal), M. Kreuter (Heidelberg, Germany)

13:15 – 14:15

Industry lunchtime symposium – Time for change? Pioneering in IPF management

Organized by: Galapagos NV. Chair: T. Maher (St Albans, UK)

Channel 3

14:20 – 15:20

Symposium - Severe thoracic sarcoidosis : where do we stand?

Chairs: R. Costello (Dublin, Ireland) K. Antoniou (Heraklion, Greece) M. Humbert (Le Kremlin-Bicetre, France)

Studio Vienna

14:30 – 15:30	Symposium - Image-based guidelines and recommendations in respiratory diseases <i>Chairs: J. van Meerbeek (Edegem, Belgium) R. Huber (Munich, Germany)</i>
Studio Milan	
15:30 – 16:30	Lungs on fire – Interstitial lung diseases? <i>Chairs: R. Costello (Dublin, Ireland) K. Antoniou (Heraklion, Greece) M. Humbert (Le Kremlin-Bicetre, France)</i>
Studio Vienna	
15:40 – 16:40	Symposium ERN-LUNG: acting for improved cross-border management of rare diseases <i>Chairs: M. Wijsenbeek (Rotterdam, Netherlands) V. Cottin (Lyon, France)</i>
Channel 1	
16:50 – 17:50	Respiratory medicine meets other disciplines – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease <i>Chairs: M. Tamm (Basel, Switzerland) G. Riemekasten (Lübeck, Germany)</i>
Channel 1	
19:15 – 20:15	Industry evening symposium - Course and Management of Fibrosing ILDs: What Do the Data Tell Us? <i>Organized by: Boehringer Ingelheim International GmbH. Chair: L. Richeldi (Roma, Italy)</i>
Channel 2	
20:30 – 21:30	Industry evening symposium – What will the decade bring in new treatment options for ILD patients? <i>Organized by : F. Hoffmann-La Roche Ltd. Chair: M. Molina-Molina (Barcelona, Spain)</i>
Channel 5	

TUESDAY 8 SEPTEMBER (PART 1)

08:00 – 09:00 Channel 1	Industry early morning symposium - Real-world data from patients with ILDs: challenges, learnings and opportunities <i>Organized by: Boehringer Ingelheim International GmbH. Chair: J. Behr (München, Germany)</i>
09:30 – 10:30 Channel 4	Oral presentation - Quantitative imaging in diffuse lung disease
10:40 – 11:40 Channel 3	Oral presentation - Sarcoidosis: from genetics to epidemiology <i>Chairs: H. Nunes (Bobigny, France) P. Spagnolo (Padova, Italy)</i>
11:40 – 12:50 Studio Vienna	Live from the clinic - Bronchoscopy and ultrasound: Interstitial and pleural diseases <i>Chairs: P. Schenk (Grimmenstein-Hochegg, Germany) M. Schuhmann (Heidelberg, Germany) G. Massard (Esch Sur Alzette, Luxembourg)</i>
11:50 – 12:50 Studio Madrid	Symposium - How much lung disease is really caused by work, and how to assess the worker who wishes who wishes to continue working? <i>Chairs: C. Suppli Ulrik (Virium, Denmark) A. Bush (London, UK)</i>
11:50 – 12:50 Studio Milan	Symposium - Lung transplantation in the era of new drugs <i>Chairs: J. van Meerbeeck (Edegem, Belgium) F. Meloni (Pavia, Italy)</i>
14:30 – 15:30 Channel 3	Oral presentation - What is new in interstitial lung diseases of known origin? <i>Chairs: B. Crestani (Paris, France) R. Borie (Paris, France)</i>
14:30 – 15:30 Studio Madrid	(Re-)discovering the small airway epithelium of COVID-19, fibrosing lung diseases and pulmonary regeneration <i>Chairs: A. Dinh-Xuan (Paris, France) N. Ubags (Epalinges, Switzerland)</i>

14:30 – 15:30 **Symposium - Fear and anxiety, psychological wellbeing and prevention of psychological distress in chronic lung diseases**

Studio Milan

Chairs: T. Troosters (Leuven, Belgium) M. Delcroix (Leuven, Belgium)

15:40 – 16:40 **Hot topics - Air pollution and interstitial lung disease: a call to arms**

Studio Madrid

Chairs: A. Dinh-Xuan (Paris, France) N. Ubags (Epalinges, Switzerland)

TUESDAY 8 SEPTEMBER (PART 2)

15:40 – 16:40 **Symposium - Reflections from the Lung Science 2020 conference**

Studio Paris

Chairs: R. Gosens (Groningen, Netherlands) M. Proesmans (Leuven, Belgium)

16:50 – 17:50 **Symposium - The ageing lung epithelium: effects on repair and regeneration**

Studio Madrid

Chairs: A. Dinh-Xuan (Paris, France) N. Ubags (Epalinges, Switzerland)

18:00 – 19:00 **Journal session – When the lung gets stiff**

Studio Madrid

Chairs: A. Dinh-Xuan (Paris, France) N. Ubags (Epalinges, Switzerland)

18:00 – 19:00 **Symposium - Human *ex vivo* models of interstitial lung disease**

Studio Paris

Chairs: R. Gosens (Groningen, Netherlands) M. Proesmans (Leuven, Belgium)

20:30 – 21:30 **Industry Evening Symposium - Supporting the patient pathway in ILD management: from early diagnosis to advanced disease**

Channel 1

Organized by : F. Hoffmann-La Roche Ltd

WEDNESDAY 9 SEPTEMBER

10:40 – 11:40

Studio Madrid

Hot topics - Interstitial lung disease patients in the intensive care unit

Chairs: C. Robalo Cordeiro (Coimbra, Portugal) N. Ubags (Epalinges, Switzerland)

11:50 – 12:50

Studio Madrid

State of the art session - Interstitial lung diseases

Chairs: C. Robalo Cordeiro (Coimbra, Portugal) N. Ubags (Epalinges, Switzerland)

11:50 – 12:50

Studio Paris

Symposium – Digital health: a brave new world?

Chairs: R. Costello (Dublin, Ireland) H Pinnock (Edinburgh, UK)

15:40 – 16:40

Channel 4

Oral presentation - Promising biomarkers for idiopathic interstitial pneumonia

Chairs: S. Ohshimo (Hiroshima, Japan) M. Funke-Chambour (Bern, Switzerland)

16:50 – 17:50

Channel 4

Oral presentation - Possible scenarios in the challenging future of rare diffuse parenchymal lung diseases

Chairs: F. Bonella (Düsseldorf, Germany) R. Borie (Paris, France)

19:15 – 20:15

Channel 1

Industry evening symposium - Management of Autoimmune Disease-Related ILDs: how can we improve outcomes for patients?

Organized by : Boehringer Ingelheim International GmbH. Chair: V. Cottin (Lyon, France)

PRE-RECORDED CONTENT

Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis

W. Wuyts

From life threatening to chronic connective tissue disease-associated interstitial lung disease: all you need to know

S. Danoff

Transbronchial cryobiopsy in diffuse parenchymal lung diseases

C. Ravagli

The role of the radiologist in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis

J. Verschakelen

MONDAY 7 SEPTEMBER

09:30 – 10:30

Channel 4

Oral presentation - New clinical insights into idiopathic pulmonary fibrosis.

Chairs: W. Wuyts (Leuven, Belgium) M. Wijsenbeek (Rotterdam, Netherlands)

09:30 Introduction

09:33 Late Breaking Abstract - Combinative analysis of RNA-seq and proteomics reveals potential molecular targets in TGF-beta1-induced fibroblast-myofibroblast transition. *Z. Wang (China)*

09:36 Monounsaturated Fatty Acid diet associates less gastrointestinal adverse events of pirfenidone: phase IV clinical trial. *E. Fontanilles Arbones (Hospitalet de Llobregat, Spain)*

09:39 To be or not to be – the uncertainty of PF-ILD. *M. Kreuter (Heidelberg, Germany)*

09:42 Genetic susceptibility and manifestation of progressive fibrosing interstitial lung diseases. *M. Šterclová (Praha, Czech Republic)*

09:45 Historical eye on idiopathic pulmonary fibrosis: redefining the mortality scenario. *S. Tomassetti (Florence, Italy)*

09:48 Development of an artificial intelligence software to detect interstitial pneumonias. *H. Nishikiori (Sapporo, Japan)*

09:51 Discussion

11:50 – 12:50

Channel 4

Challenging clinical cases – Interstitial lung diseases

Chairs: M. Kreuter (Heidelberg, Germany) M. Molina-Molina (Barcelona, Spain)

11:50 Introduction

11:55 A challenging complex complication in common variable immune deficiency. *S. Zimmermann (Sydney, Australia)*

12:06 Granulomatous lung disease in lymphoma patient after rituximab treatment. *P. Janowiak (Gdańsk, Poland)*

12:17 A crazy conundrum. *N. Imambaccus (London, UK)*

12:28 A rare cause of recurrent pneumothorax. *J. Oliveira Pereira (Coimbra, Portugal)*

12:39 Pleural effusion in Niemann Pick Disease - associated Interstitial Lung Disease. *E. Boynton (Cambridge, UK)*

13:15 – 14:15

Channel 3

Industry lunchtime symposium – Time for change? Pioneering in IPF management

Organized by: Galapagos NV

Chair: T. Maher (St Albans, UK)

13:15 Time for change? Opening address. *T. Maher (St. Albans, UK)*

13:20 Novel imaging modalities in interstitial lung disease. *P. Ford (Hurstpierpoint, UK) M. Thillai (Cambridge, UK)*

13:35 Maintaining the momentum: Ensuring optimal management 6MWT in IPF. *L. Lancaster (Nashville, USA)*

13:50 ISABELA: A landmark study in IPF. *T. Maher (St. Albans, UK)*

14:05 Q&A and closing remarks T. Maher (St. Albans, UK) L. Lancaster (Nashville, USA) P. Ford (Hurstpierpoint, UK) M. Thillai (Cambridge, UK)

14:20 – 15:20

Studio Vienna

Symposium - Severe thoracic sarcoidosis : where do we stand?

Chairs: R. Costello (Dublin, Ireland) K. Antoniou (Heraklion, Greece) M. Humbert (Le Kremlin-Bicetre, France)

14:20 Introduction

14:25 Pathogenesis of pulmonary fibrosis in sarcoidosis. J. Grutters (Nieuwegein, Netherlands)

14:35 Genetic and non-genetic risk factors for severe pulmonary sarcoidosis. P. Spagnolo (Padova, Italy)

14:50 Severe pulmonary sarcoidosis: definition and risk stratification. D. Culver (Cleveland, USA)

14:55 Management of cardiac sarcoidosis. V. Kouranos (London, UK)

15:10 Discussion and Q&As

14:30 – 15:30

Studio Milan

Symposium - Image-based guidelines and recommendations in respiratory diseases

Chairs: J. van Meerbeeck (Edegem, Belgium) R. Huber (Munich, Germany)

14:30 Introduction

14:35 Incidental or screen based findings of pulmonary nodules: what to do? A. Dubbeldam (Nieuwrode, Belgium)

14:45 Revised diagnostic criteria for idiopathic pulmonary fibrosis. A. Wells (London, UK)

14:55 Logical use of imaging modalities in lung cancer staging. W. de Wever (Leuven, Belgium)

15:05 Image-based recommendations for the evaluation of pulmonary embolism and arterial hypertension: what? when? how?
M. Remy-Jardin (Lille, France)

15:15 Discussion and Q&A

15:30 – 16:30

Studio Vienna

Lungs on fire – Interstitial lung diseases?

Chairs: R. Costello (Dublin, Ireland) K. Antoniou (Heraklion, Greece) M. Humbert (Le Kremlin-Bicetre, France)

15:30 Introduction

15:32 Presentation of cases by the session facilitator. N. Chaudhuri (Manchester, UK)

Case 1 - Author: Hebatallah Hany Assal (Egypt)

Case 2 - Author: Neel Thakkar (India)

Case 3 - Author: João Oliveira Pereira (Portugal)

Case 4 - Author: Oleh Yakovenko (Ukraine)

15:40 – 16:40

Channel 1

Symposium ERN-LUNG: acting for improved cross-border management of rare diseases

Chairs: M. Wijsenbeek (Rotterdam, Netherlands) V. Cottin (Lyon, France)

15:40 Introduction

15:45 ERN-lung report from the network coordination team. G. Rohde (Frankfurt am Main, Germany)

15:54 Phenotypic Spectrum in Primary Ciliary Dyskinesia. H. Omran (Münster, Germany)

- 16:03 Genomically-guided therapies: a new era for cystic fibrosis. *M. Mall (Berlin, Germany)*
- 16:12 Why should we care for the vessels in interstitial lung disease? *H. Olschewski (Graz, Austria)*
- 16:21 Immundefects, rare pulmonary infections and rare lung diseases. *J. Hurst (London, UK)*
- 16:30 Discussion and Q&A

16:50 – 17:50
Channel 1

Respiratory medicine meets other disciplines – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease

Chairs: M. Tamm (Basel, Switzerland) G. Riemekasten (Lübeck, Germany)

- 16:50 Introduction
- 16:55 Interstitial lung disease (ILD) and multicompartiment assessment of CTD: where should the respiratory physician begin? *C. Denton (London, UK)*
- 17:05 Does histology matter in ILD-CTD? *V. Poletti (Forlì, Italy)*
- 17:15 Fibrotic CTD and interstitial pneumonia with autoimmune features (IPAF): immunosuppressive or/and anti-fibrotic treatment? *S. Danoff (Baltimore, USA)*
- 17:25 B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all? *D. Kyburz (Basel, Switzerland)*
- 17:35 Discussion and Q&A

19:15 – 20:15
Channel 2

Industry evening symposium - Course and Management of Fibrosing ILDs: What Do the Data Tell Us?

Organized by: Boehringer Ingelheim International GmbH

Chair: L. Richeldi (Roma, Italy)

- 19:15 Welcome and introduction. *L. Richeldi (Roma, Italy)*
- 19:25 The natural history of fibrosing ILDs. *M. Wijsenbeek (Rotterdam, Netherlands)*
- 19:35 Fibrosing ILDs: splitting and lumping. *E. Renzoni (London, UK)*
- 19:45 Key insights from the INBUILD trial. *K. Flaherty (Pinckney, USA)*
- 20:00 Panel discussion. *L. Richeldi (Roma, Italy) M. Wijsenbeek (Rotterdam, Netherlands) E. Renzoni (London, UK) K. Flaherty (Pinckney, USA)*

20:30 – 21:30
Channel 5

Industry evening symposium – What will the decade bring in new treatment options for ILD patients?

Organized by : F. Hoffmann-La Roche Ltd

Chair: M. Molina-Molina (Barcelona, Spain)

- 20:30 Opening remarks. *M. Molina Molina (Barcelona, Spain)*
- 20:35 What will ILD management beyond IPF look like? *A. Hoffmann-Vold (Oslo, Norway) C. Vancheri (Catania, Italy)*
- 20:55 The promising future of IPF treatment. *V. Cottin (Lyon, France)*
- 21:10 Q&A. *A. Hoffmann-Vold (Oslo, Norway) C. Vancheri (Catania, Italy) V. Cottin (Lyon, France)*
- 21:25 Closing remarks. *M. Molina Molina (Barcelona, Spain)*

TUESDAY 8 SEPTEMBER

08:00 – 09:00

Channel 1

Industry early morning symposium - Real-world data from patients with ILDs: challenges, learnings and opportunities

Organized by: Boehringer Ingelheim International GmbH

Chair: J. Behr (München, Germany)

08:00 Welcome and introduction. *J. Behr (München, Germany)*

08:15 Interpreting real-world data from patients with ILDs. *J. Behr (München, Germany)*

08:25 What have registry data told us about the diagnosis and management of IPF? *T. Corte (Camperdown, Australia)*

08:40 Patient registries in ILDs: what might they teach us in the future? *D. Culver (Cleveland, USA)*

08:50 Panel discussion. *J. Behr (München, Germany) T. Corte (Camperdown, Australia) D. Culver (Cleveland, USA)*

09:30 – 10:30

Channel 4

Oral presentation - Quantitative imaging in diffuse lung disease

Chairs: ?

09:30 Introduction

09:33 Oxygen enhanced MRI biomarkers of lung function in interstitial lung disease. *J. Waterton (Manchester, UK)*

09:36 Quantitative analysis of paired inspiratory and expiratory CT correlates highly with lung function measurements in COPD patients under tiotropium-olodaterol respimat. *F. Herth (Heidelberg, Germany)*

09:39 Ventilation defect quantification on 3He MRI through deep learning: the MESA COPD Study. *X. Zhang (New York, USA)*

09:42 Regional hyperpolarised 129-xenon diffusion-weighted MRI in patients with IPF. *J. Eaden (Sheffield, UK)*

09:45 Robust automatic segmentation of airway using multi-resolution deep learning. *S. Bonte (Kontich, Belgium)*

09:48 Discussion

10:40 – 11:40

Channel 3

Oral presentation - Sarcoidosis: from genetics to epidemiology

Chairs: H. Nunes (Bobigny, France) P. Spagnolo (Padova, Italy)

10:40 Introduction

10:43 Whole Exome Sequencing in familial sarcoidosis targets pathways which may help early diagnosis of severe forms of sarcoidosis. *A. Calender (Lyon, France)*

10:46 Active clinical pulmonary sarcoidosis is characterized by significantly reduced apoptosis rate of alveolar lymphocytes (AL). *T. Wandtke (Bydgoszcz, Poland)*

10:49 Autophagy is closely related to the inflammatory process in sarcoidosis uveitis. *T. EL JAMMAL (Strasbourg, France)*

10:52 Exhaled breath analysis using eNose technology in patients with sarcoidosis. *C. Moor (Rotterdam, Netherlands)*

10:55 The autoimmune criteria of sarcoidosis. *A. Starshinova (St. Petersburg, Russian Federation)*

10:58 Mortality in a well-defined group of predominantly caucasian pulmonary sarcoidosis patients. *M. Huitema (Utrecht, Netherlands)*

11:01 Type 2 diabetes mellitus risk associated with sarcoidosis: A Swedish population-based cohort study. *E. Arkema (Stockholm, Sweden)*

11:04 Discussion

11:40 – 12:50

Studio Vienna

Live from the clinic - Bronchoscopy and ultrasound: Interstitial and pleural diseases

Chairs: P. Schenk (Grimmenstein-Hohegg, Germany) M. Schuhmann (Heidelberg, Germany) G. Massard (Esch Sur Alzette, Luxembourg)

11:40 Introduction

11:45 Endobronchial ultrasound and trans-esophageal endobronchial ultrasound: sarcoidosis. *L. Crombag (Amsterdam, Netherlands) K. Mooij - Kalverda (Amsterdam, Netherlands)*

12:00 Cryobiopsy, confocal laser endomicroscopy and optical coherence tomography in lung fibrosis. *P. Bonta (Amsterdam, Netherlands) L. Wijmans (Amsterdam, Netherlands) K. Mooij - Kalverda (Amsterdam, Netherlands)*

12:10 Thoracic ultrasound: pleural effusion and empyema. *N. Rahman (Oxford, UK)*

12:20 Thoracic ultrasound: COVID-19. *C. Laursen (Odense, Denmark)*

12:30 Rigid thoracoscopy. *J. Daniels (Amsterdam, Netherlands) P. Bonta (Amsterdam, Netherlands)*

12:45 Discussion and Q&A

11:50 – 12:50

Studio Madrid

Symposium - How much lung disease is really caused by work, and how to assess the worker who wishes who wishes to continue working?

Chairs: C. Suppli Ulrik (Virium, Denmark) A. Bush (London, UK)

11:50 Introduction

11:55 COPD and bronchitis; how much is caused by work, and which occupations cause the most harm? *D. Fishwick (Sheffield, UK)*

12:04 Wheeze and crackles: how much does the workplace contribute? *I. Annesi Maesano (Paris, France)*

12:13 Rare lung diseases and work: always bear occupation in mind when assessing these patients. *D. Vinnikov (Almaty, Kazakhstan)*

12:22 How important is work as a risk for lung infections? A story of tuberculosis and pneumonia. *N. Naidoo (Durban, South Africa)*

12:31 Work, workplace and fitness considerations in patients with occupational lung diseases. *C. Barber (Sheffield, UK)*

12:40 Discussion and Q&A

11:50 – 12:50

Studio Milan

Symposium - Lung transplantation in the era of new drugs

Chairs: J. van Meerbeeck (Edegem, Belgium) F. Meloni (Pavia, Italy)

11:50 Introduction

- 11:55 The need for lung transplantation in cystic fibrosis (CF) in the era of new treatment. *C. Benden (Berne, Switzerland)*
- 12:05 New antifibrotic drugs: will interstitial diseases patients still need lung transplantation? *S. Tomassetti (Florence, Italy)*
- 12:15 New issues in lung transplantation for pulmonary hypertension. *M. Delcroix (Leuven, Belgium)*
- 12:25 Figures and outcomes of lung transplantation. *J. Gottlieb (Hannover, Germany)*
- 12:35 Discussion and Q&A

14:30 – 15:30
Channel 3

Oral presentation - What is new in interstitial lung diseases of known origin?

Chairs: B. Crestani (Paris, France) R. Borie (Paris, France)

- 14:30 Introduction
- 14:33 LSC - 2020 - The respiratory microbiome and metabolome in chronic hypersensitivity pneumonitis. *R. Invernizzi (London, UK)*
- 14:36 Methotrexate and risk of Lung disease in Rheumatoid Arthritis: A nationwide population-based cohort study from Denmark
S. Shaker (Hellerup, Denmark)
- 14:39 Combined assessment of regional lung function and morphology using a contrast enhanced Dual-Energy CT protocol: Prospective value of functional imaging biomarkers in longitudinal analysis of patients with Interstitial Lung Disease. *S. Scharm (Hannover, Germany)*
- 14:45 Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids? *N. Chaudhuri (Manchester, UK)*
- 14:48 Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial. *C. Valenzuela (Madrid, Spain)*
- 14:51 Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial. *K. Flaherty (Pinckney, USA)*
- 14:54 Discussion

14:30 – 15:30
Studio Madrid

(Re-)discovering the small airway epithelium of COVID-19, fibrosing lung diseases and pulmonary regeneration

Chairs: A. Dinh-Xuan (Paris, France) N. Ubags (Epalinges, Switzerland)

- 14:30 Introduction
- 14:35 The role of bronchial epithelial cells in COVID-19 infection and pathogenesis. *R. Eils (Heidelberg, Germany)*
- 14:45 Airway basal cell involvement in idiopathic pulmonary fibrosis. *A. Prasse (Hannover, Germany)*
- 14:55 Uncovering the plasticity of lung epithelial cells by scRNA sequencing. *H. Schiller (Munich, Germany)*
- 15:05 Modeling the regenerative potential of airway epithelial cells. *P. Hiemstra (Leiden, Netherlands)*
- 15:15 Discussion and Q&A

14:30 – 15:30
Studio Milan

Symposium - Fear and anxiety, psychological wellbeing and prevention of psychological distress in chronic lung diseases

Chairs: T. Troosters (Leuven, Belgium) M. Delcroix (Leuven, Belgium)

- 14:30 Introduction
- 14:35 Patient perspective: video. *R. Flewett (UK)*
- 14:40 Disease-specific fears in COPD. *T. Reijnders (Heverlee, Belgium)*
- 14:50 Nurse-led cognitive behavioral therapy in COPD. *K. Heslop-Marshall (Newcastle upon Tyne, UK)*
- 15:00 Expressing empathy in 15 minutes or less: challenges for clinicians. *D. Reynolds-Sandford (Adelaide, Australia)*
- 15:10 Integrating early palliative care for patients with idiopathic pulmonary fibrosis and their caregivers. *K. Lindell (Pittsburgh, USA)*
- 15:20 Discussion and Q&A

15:40 – 16:40

Studio Madrid

Hot topics - Air pollution and interstitial lung disease: a call to arms

Chairs: A. Dinh-Xuan (Paris, France) N. Ubags (Epalinges, Switzerland)

- 15:40 Introduction
- 15:45 Genetic predisposition and the environment. *M. Molina Molina (Barcelona, Spain)*
- 15:54 Air pollution: particle size matters. *H. Davies (Vancouver, Canada)*
- 16:03 Interstitial lung disease and air pollution: in India and beyond. *S. Singh (Jaipur, India)*
- 16:12 Intrinsic and extrinsic environmental factors in IPF. *G. Raghu (Seattle, USA)*
- 16:21 Microbiome effects on immunity, health and diseases of the lungs. *K. Antoniou (Heraklion, Greece)*
- 16:30 Discussion and Q&A

15:40 – 16:40

Studio Paris

Symposium - Reflections from the Lung Science 2020 conference

Chairs: R. Gosens (Groningen, Netherlands) M. Proesmans (Leuven, Belgium)

- 15:40 Introduction
- 15:45 An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. *H. Schiller (Munich, Germany)*
- 15:54 The promise of mTOR signaling as a therapeutic target for IPF
- 16:03 Itaconate controls the severity of pulmonary fibrosis. *P. Ogger (London, UK)*
- 16:12 Versatile workflow for storage, characterization and celltype resolved transcriptional and epigenetic profiling of human lung samples. *R. Jurkowska (Cardiff, UK)*
- 16:21 Mitochondrial iron in the susceptibility, pathogenesis and progression of COPD. *S. Cloonan (New York City, USA)*
- 16:30 Discussion and Q&A

16:50 – 17:50

Studio Madrid

Symposium - The ageing lung epithelium: effects on repair and regeneration

Chairs: A. Dinh-Xuan (Paris, France) N. Ubags (Epalinges, Switzerland)

- 16:50 Introduction
- 16:55 Targeting the lung epithelium: does age matter? *P. Wolters (San Francisco, USA)*
- 17:05 Senescence and immune ageing. *M. Rojas (Pittsburgh, USA)*

- 17:15 Cellular senescence in regeneration and diseases of the lung. *M. Lehmann (München, Germany)*
17:25 The inflammatory niche of the aged lung. *L. Donnelly (London, UK)*
17:35 Discussion and Q&A

18:00 – 19:00
Studio Madrid

Journal session – When the lung gets stiff

Chairs: A. Dinh-Xuan (Paris, France) N. Ubags (Epalinges, Switzerland)

- 18:00 Introduction. *J. Drazen (Boston, USA)*
18:05 Idiopathic pulmonary fibrosis (IPF): epidemiology, biology, diagnosis and treatment. *F. Martinez (New York, USA)*
18:15 Interstitial lung diseases (ILDs) secondary to other conditions: common biology, epidemiology, diagnosis and treatment. *M. Wijsenbeek (Rotterdam, Netherlands)*
18:25 Pro-con debate: Does it make sense to view rapidly progressive ILD as a distinct clinical entity? – CON. *V. Cottin (Lyon, France)*
18:35 Pro-con debate: Does it make sense to view rapidly progressive ILD as a distinct clinical entity? – PRO. *E. Renzoni (London, UK)*
18:45 Discussion and Q&A
18:55 Conclusion. *J. Drazen (Boston, USA)*

18:00 – 19:00
Studio Paris

Symposium - Human *ex vivo* models of interstitial lung disease

Chairs: R. Gosens (Groningen, Netherlands) M. Proesmans (Leuven, Belgium)

- 18:00 Introduction
18:05 3D tissue culture to study the mechanisms of lung repair in IPF. *M. Konigshoff (Denver, USA)*
18:15 Using induced pluripotent stem cells to study the type II pneumocyte. *K. Hurley (Dublin, Ireland)*
18:25 Lung-on-a-chip: state of the art. *N. Roldan (Bern, Switzerland)*
18:35 The role of cell lines in modelling the type II pneumocyte in interstitial lung disease. *J. Dickens (Cambridge, UK)*
18:45 Discussion and Q&A

20:30 – 21:30
Channel 1

Industry Evening Symposium - Supporting the patient pathway in ILD management: from early diagnosis to advances disease

Organized by : F. Hoffmann-La Roche Ltd

- 20:30 Opening remarks. *S. Nathan (Falls Church, USA)*
20:35 Panel Discussion: How do we ensure early and specific diagnosis of ILDs? *S. Nathan (Falls Church, USA) M. Wijsenbeek (Rotterdam, Netherlands) E. Bendstrup (Vejle, Denmark) N. Sverzellati (Parma, Italy)*
21:05 Short recap of interview: What are current treatment challenges for non-IPF ILDs? *M. Kreuter (Heidelberg, Germany)*
21:15 Short talk: What do we do with ILD patients with more advanced functional impairment? *S. Nathan (Falls Church, USA) E. Bendstrup (Vejle, Denmark)*

WEDNESDAY 9 SEPTEMBER

10:40 – 11:40

Studio Madrid

Hot topics - Interstitial lung disease patients in the intensive care unit

Chairs: C. Robalo Cordeiro (Coimbra, Portugal) N. Ubags (Epalinges, Switzerland)

10:40 Introduction

10:45 Selection of ILD patients for ICU and ECMO. *C. Agerstrand (New York, USA)*

10:55 Radiological patterns in ICU: does it matter? *N. Sverzellati (Parma, Italy)*

11:05 Diagnostic procedures in ICU: bronchoscopy and BAL or tissue? *C. Ravaglia (Forlì, Italy)*

11:15 Management of ILD patients in ICU. *M. Kokosi (London, UK)*

11:25 Discussion and Q&A

11:50 – 12:50

Studio Madrid

State of the art session - Interstitial lung diseases

Chairs: C. Robalo Cordeiro (Coimbra, Portugal) N. Ubags (Epalinges, Switzerland)

11:50 Introduction

11:55 Chronic Hypersensitivity pneumonitis: risks factors and therapeutic options. *A. Wells (London, UK)*

12:05 Genetics in ILDs: what does the future hold? *M. Molina Molina (Barcelona, Spain)*

12:15 Invasive approaches in the diagnosis of ILDs. *C. Ravaglia (Forlì, Italy)*

12:25 How systemic inflammatory diseases affect the lung. *M. Kreuter (Heidelberg, Germany)*

12:35 Discussion and Q&A

11:50 – 12:50

Studio Paris

Symposium – Digital health: a brave new world?

Chairs: R. Costello (Dublin, Ireland) H Pinnock (Edinburgh, UK)

11:50 Introduction

11:55 Let's start with the end-user, patients and digital: will they work together? *D. Hamerlijnck (Amsterdam, Netherlands)*

12:00 Combining digital technologies to monitor asthma control and predict asthma exacerbations. *O. Usmani (London, UK)*

12:10 New horizons in digital technologies for respiratory medicine. *V. Poberezhets (Vinnytsia, Ukraine)*

12:20 Designs of future digital trials and the promise of artificial intelligence. *K. Kostikas (Ioannina, Greece)*

12:30 Connected health and eHealth literacy. *L. Kayser (Copenhagen, Denmark)*

12:40 Discussion and Q&A

15:40 – 16:40

Channel 4

Oral presentation - Promising biomarkers for idiopathic interstitial pneumonia

Chairs: S. Ohshimo (Hiroshima, Japan) M. Funke-Chambour (Bern, Switzerland)

15:40 Introduction

15:43 Biomarkers of collagen formation are predictive of IPF progression and death. *N. Hoyer (København NV, Denmark)*

- 15:46 Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial. *G. Jenkins (Nottingham, UK)*
- 15:49 Association of neoepitopes with disease severity and respiratory hospitalization in patients with IPF. *J. Oldham (Sacramento, USA)*
- 15:52 Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial. *E. White (Ann Arbor, USA)*
- 15:55 Prognostic value of oxygenated hemoglobin (OxyHem) in fibrosing interstitial lung diseases. *S. Torrisi (Acireale, Italy)*
- 15:58 Diagnosis of interstitial lung diseases using eNose technology. *C. Moor (Rotterdam, Netherlands)*
- 16:01 Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis. *K. Yamaguchi (Hiroshima, Japan)*
- 16:04 Discussion

16:50 – 17:50
Channel 4

Oral presentation - Possible scenarios in the challenging future of rare diffuse parenchymal lung diseases

Chairs: F. Bonella (Düsseldorf, Germany) R. Borie (Paris, France)

- 16:50 Introduction
- 16:56 The long-term outcome of adult pulmonary Langerhans cell histiocytosis: a national registry-based prospective cohort study. *A. Benattia (Paris (Île-de-France), France)*
- 16:59 Bronchoalveolar lavage cytokine profile in patients with Pulmonary Langerhans Cell Histiocytosis differs from other interstitial lung diseases. *D. Castillo Villegas (Barcelona, Spain)*
- 17:02 Interstitial lung diseases associated with mutations of poly(A)-specific ribonuclease: a multicentric retrospective cohort study. *Q. Philippot (Paris, France)*
- 17:05 Increase in post-transplant survival and quality of life in pulmonary fibrosis with and without telomere dysfunction. *L. Planas Cerezales (Hospitalet de Llobregat, Spain)*
- 17:08 Acute exacerbation in combined pulmonary fibrosis and emphysema (CPFE): what special features? *H. Mrassi (Tunis, Tunisia)*
- 17:11 Assessment of fibrosis in lung biopsies from the European childhood interstitial lung disease (chILD) registry. *M. Griese (München, Germany)*
- 17:14 Discussion

19:15 – 20:15
Channel 1

Industry evening symposium - Management of Autoimmune Disease-Related ILDs: how can we improve outcomes for patients?

Organized by : Boehringer Ingelheim International GmbH

Chair: V. Cottin (Lyon, France)

- 19:15 Welcome and introduction. *V. Cottin (Lyon, France)*
- 19:25 Optimising the monitoring and treatment of SSc-ILD. *A. Hoffmann-Vold (Oslo, Norway)*

- 19:40 Pulmonary manifestations of autoimmune diseases beyond SSc – what do we have to consider? *M. Kreuter (Heidelberg, Germany)*
- 19:55 Panel discussion. *V. Cottin (Lyon, France) A. Hoffmann-Vold (Oslo, Norway) M. Kreuter (Heidelberg, Germany)*